VAS
NVO

Vestmark Advisory Solutions’s Novo Nordisk NVO Stock Holding History

Vestmark Advisory Solutions’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.83M Sell
142,411
-14,534
-9% -$624K 0.06% 313
2026
Q1 		$5.77M Buy
156,945
+28,548
+22% +$1.35M 0.06% 311
2025
Q4 		$6.53M Buy
128,397
+68,501
+114% +$3.5M 0.09% 237
2025
Q3 		$3.32M Buy
59,896
+7,948
+15% +$465K 0.06% 310
2025
Q2 		$3.59M Buy
51,948
+5,912
+13% +$402K 0.05% 273
2025
Q1 		$3.2M Buy
46,036
+19,413
+73% +$1.6M 0.08% 268
2024
Q4 		$2.29M Buy
26,623
+614
+2% +$66.4K 0.08% 239
2024
Q3 		$3.1M Sell
26,009
-598
-2% -$79.8K 0.12% 191
2024
Q2 		$3.8M Sell
26,607
-587
-2% -$77.8K 0.16% 144
2024
Q1 		$3.49M Sell
27,194
-435
-2% -$51.8K 0.15% 162
2023
Q4 		$2.86M Sell
27,629
-1,788
-6% -$177K 0.15% 178
2023
Q3 		$2.68M Sell
29,417
-38,973
-57% -$3.43M 0.19% 131
2023
Q2 		$5.53M Buy
68,390
+1,988
+3% +$162K 0.21% 124
2023
Q1 		$5.28M Sell
66,402
-4,998
-7% -$354K 0.23% 118
2022
Q4 		$4.83M Sell
71,400
-244
-0.3% -$14.3K 0.24% 110
2022
Q3 		$3.57M Sell
71,644
-5,532
-7% -$296K 0.2% 133
2022
Q2 		$4.3M Buy
77,176
+21,400
+38% +$1.19M 0.25% 97
2022
Q1 		$3.1M Sell
55,776
-4,936
-8% -$253K 0.18% 142
2021
Q4 		$3.4M Buy
60,712
+68
+0.1% +$3.68K 0.19% 118
2021
Q3 		$2.91M Buy
60,644
+14,006
+30% +$677K 0.2% 125
2021
Q2 		$1.95M Buy
46,638
+9,938
+27% +$385K 0.14% 193
2021
Q1 		$1.24M Sell
36,700
-1,650
-4% -$58.8K 0.11% 248
2020
Q4 		$1.34M Buy
38,350
+652
+2% +$22.5K 0.15% 189
2020
Q3 		$1.31M Buy
37,698
+2,670
+8% +$89K 0.18% 166
2020
Q2 		$1.15M Sell
35,028
-776
-2% -$24.8K 0.18% 161
2020
Q1 		$1.08M Buy
35,804
+1,912
+6% +$56.9K 0.21% 153
2019
Q4 		$981K Buy
33,892
+8,646
+34% +$239K 0.2% 152
2019
Q3 		$653K Buy
25,246
+4,384
+21% +$111K 0.11% 248
2019
Q2 		$532K Buy
20,862
+1,570
+8% +$38.8K 0.09% 267
2019
Q1 		$505K Buy
+19,292
New +$474K 0.09% 278

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Vestmark Advisory Solutions's NVO Position: Q2 2026 in Review

Vestmark Advisory Solutions reduced its Novo Nordisk (NVO) stake by 9.3% in Q2 2026, selling an estimated $624K and leaving 142,411 shares worth $6.83M. The position accounts for 0.06% of the portfolio, ranked #313.

Vestmark Advisory Solutions first reported a position in NVO in Q1 2019 and has held it in 30 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Vestmark Advisory Solutions held 142,411 shares of Novo Nordisk worth $6.83M as of Q2 2026.
  • Vestmark Advisory Solutions sold 14,534 Novo Nordisk shares in Q2 2026, an estimated $624K.
  • Novo Nordisk made up 0.06% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #313 holding.
  • Vestmark Advisory Solutions first reported a position in Novo Nordisk in Q1 2019 and has held it in 30 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.